Oncodesign Precision Medicine SA (ALOPM)

Currency in EUR
0.32
-0.02(-5.59%)
Real-time Data·
ALOPM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.320.32
52 wk Range
0.310.92
Key Statistics
Prev. Close
0.34
Open
0.32
Day's Range
0.32-0.32
52 wk Range
0.31-0.92
Volume
6.51K
Average Volume (3m)
11.45K
1-Year Change
-23.2057%
Book Value / Share
0.32
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALOPM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral

Earnings

Latest Release
Jun 03, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ALOPM Income Statement

Compare ALOPM to Peers and Sector

Metrics to compare
ALOPM
Peers
Sector
Relationship
P/E Ratio
1.2x−2.5x−0.4x
PEG Ratio
0.01−0.070.00
Price/Book
1.1x0.6x2.6x
Price / LTM Sales
3.6x10.8x3.0x
Upside (Analyst Target)
-134.7%51.8%
Fair Value Upside
Unlock7.1%7.2%Unlock

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
158.04K0.83%53.73K
Other Institutional Investors
8.93M46.88%3.04M
Public Companies & Retail Investors
9.96M52.29%3.38M
Total
19.04M100.00%6.47M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Raymond James Wealth Management Limited46.88%8,927,0023,035
Ofi Invest Asset Management0.83%158,03754

People Also Watch

0.2870
ALSEN
-2.05%
109.50
ABVX
+0.37%
4.415
ALTHX
-3.71%
1.0000
ALGID
+0.40%
0.804
ALVAL
+2.42%

FAQ

What Is the Oncodesign Precision Medicine (ALOPM) Stock Price Today?

The Oncodesign Precision Medicine stock price today is 0.32 EUR.

What Stock Exchange Does Oncodesign Precision Medicine Trade On?

Oncodesign Precision Medicine is listed and trades on the Paris Stock Exchange.

What Is the Stock Symbol for Oncodesign Precision Medicine?

The stock symbol for Oncodesign Precision Medicine is "ALOPM."

What Is the Oncodesign Precision Medicine Market Cap?

As of today, Oncodesign Precision Medicine market cap is 6.47M EUR.

What Is Oncodesign Precision Medicine's Earnings Per Share (TTM)?

The Oncodesign Precision Medicine EPS (TTM) is 0.30.

When Is the Next Oncodesign Precision Medicine Earnings Date?

Oncodesign Precision Medicine will release its next earnings report on Sep 22, 2026.

From a Technical Analysis Perspective, Is ALOPM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Oncodesign Precision Medicine Stock Split?

Oncodesign Precision Medicine has split 0 times.

What is the current trading status of Oncodesign Precision Medicine (ALOPM)?

As of Aug 06, 2026, Oncodesign Precision Medicine (ALOPM) is trading at a price of 0.32 EUR, with a previous close of 0.34 EUR. The stock has fluctuated within a day range of 0.32 EUR to 0.32 EUR, while its 52-week range spans from 0.31 EUR to 0.92 EUR.

What Is Oncodesign Precision Medicine (ALOPM) Price Target According to Analysts?

The average 12-month price target for Oncodesign Precision Medicine is 2.00 EUR, with a high estimate of 2 EUR and a low estimate of 2 EUR. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +525.00% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.